Synthetic biology company secures major supply and licensing contract

Synthetic biology company, Oxford Genetics, has secured a major supply and licensing contract, worth millions, with a global ecommerce provider of reagents and tools to the research and clinical community.

Under the terms of the agreement, Oxford Genetics will leverage its high throughput automated genomic engineering platform for CRISPR modification of mammalian cell lines.

“This contract highlights Oxford Genetics’ commitment to providing the highest quality cell line engineering services to its global customer base and continuing to add value to their operations,” said Ryan Cawood, CEO, Oxford Genetics. “We have moved away from manual processing, which is the norm in this market, in favour of automated, scalable platforms.

“This approach means we are well positioned to deliver the large number of custom-engineered cell lines per year that the global market is forecast to need.

“We are excited about this project which will see us significantly expand our product portfolio and continue to deliver innovative products and solutions to the pharmaceutical industry.”

Oxford Genetics is headquartered in Oxford in the UK and is dedicated to developing and delivering technologies and services to customers to help change the gene editing industry. Through its use of automation, the company has developed new and innovative solutions, the latest of which is its mammalian CRISPR cell line engineering platform.